OCT devices hold promise

Article

The future of OCT seems almost limitless and for Dr Jay S. Duker, many more new innovations are expected.

The future of OCT seems almost limitless and for Dr Jay S. Duker, many more new innovations are expected.

"The OCT story is one of engineering success triumphing over darkness," said Dr Duker. In looking at the history of the technology he explained that time domain was very useful but not perfect with registration errors, skip areas, software breakdowns and, often, inadequate resolution. Spectral domain technology has been commercially available since 2006 and is faster than the previous time domain OCT.

However, in Dr Duker's opinion the innovations do not stop there. "We will see better light sources with broader bandwidths that theoretically get axial resolution down to 1 µm," he said. Not only this, but he believes there will be longer wavelengths in the future that will enable better penetration of the optic nerve and choroid for better disease insight and less scattering to improve through-cataract imaging.

Increased speed is another advancement that will happen soon. The swept source OCT is set to become commercially available shortly and will offer much faster scan speeds. Dr Duker explained that these quicker devices will also provide a higher pixel density to allow visualization of high-quality images.

"High speed over large areas will provide beautiful video images that will allow cross-sectional scans to be obtained of virtually any retinal layer from the inner retina to the capillaries to the outer retina and into the optic nerve," he added. "This technology might even supplant fluorescein angiography and even indocyanine green angiography…"

If you would like to read more about the promise OCT devices hold, Dr Duker's article can be found in the May print issue of OTEurope.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.